Longfei Jia1, Qiongqiong Qiu1, Heng Zhang1, Lan Chu2, Yifeng Du3, Jiewen Zhang4, Chunkui Zhou5, Furu Liang6, Shengliang Shi7, Shan Wang8, Wei Qin1, Qi Wang1, Fangyu Li1, Qigeng Wang1, Yan Li1, Luxi Shen1, Yiping Wei1, Jianping Jia9. 1. Innovation Center for Neurological Disorders, Department of Neurology, Xuanwu Hospital, Capital Medical University, Beijing, P.R.China. 2. Department of Neurology, the Affiliated Hospital of Guizhou Medical University, Guizhou, P.R.China. 3. Department of Neurology, Shandong Provincial Hospital, Jinan, P.R.China. 4. Department of Neurology, the Henan Provincial Peoples Hospital, Zhengzhou, P.R.China. 5. Department of Neurology, the First Hospital of Jilin University, Jilin, P.R.China. 6. Department of Neurology, Baotou Central Hospital, Baotou, P.R.China. 7. Department of Neurology, the First Affiliated Hospital of Guangxi Medical University, Nanning, P.R.China. 8. Department of Neurology, the Second Hospital of Hebei Medical University, Shijiazhuang, P.R.China. 9. Innovation Center for Neurological Disorders, Department of Neurology, Xuanwu Hospital, Capital Medical University, Beijing, P.R.China. Electronic address: jjp@ccmu.edu.cn.
Abstract
INTRODUCTION: Neuronal-derived exosomal Aβ42, T-tau, and P-T181-tau have been demonstrated to be biomarkers of Alzheimer's disease (AD). However, no study has assessed the association of Aβ42, T-tau, and P-T181-tau between exosomes and CSF. METHODS: This was a multicenter study with two-stage design. The subjects included 28 AD patients, 25 aMCI patients, and 29 controls in the discovery stage; the results of which were confirmed in the validation stage (73 AD, 71 aMCI, and 72 controls). RESULTS: The exosomal concentrations of Aβ42, T-tau, and P-T181-tau in AD group were higher than those in aMCI and control groups (all P < .001). The level of each exosomal biomarker was highly correlated with that in CSF. DISCUSSION: This study verified the agreement between CSF and blood exosomal biomarkers and confirmed that exosomal Aβ42, T-tau, and P-T181-tau have the same capacity as those in CSF for the diagnosis of AD and aMCI.
INTRODUCTION: Neuronal-derived exosomal Aβ42, T-tau, and P-T181-tau have been demonstrated to be biomarkers of Alzheimer's disease (AD). However, no study has assessed the association of Aβ42, T-tau, and P-T181-tau between exosomes and CSF. METHODS: This was a multicenter study with two-stage design. The subjects included 28 ADpatients, 25 aMCI patients, and 29 controls in the discovery stage; the results of which were confirmed in the validation stage (73 AD, 71 aMCI, and 72 controls). RESULTS: The exosomal concentrations of Aβ42, T-tau, and P-T181-tau in AD group were higher than those in aMCI and control groups (all P < .001). The level of each exosomal biomarker was highly correlated with that in CSF. DISCUSSION: This study verified the agreement between CSF and blood exosomal biomarkers and confirmed that exosomal Aβ42, T-tau, and P-T181-tau have the same capacity as those in CSF for the diagnosis of AD and aMCI.
Authors: Pavan Bhargava; Carlos Nogueras-Ortiz; Sol Kim; Francheska Delgado-Peraza; Peter A Calabresi; Dimitrios Kapogiannis Journal: Mult Scler Date: 2020-06-17 Impact factor: 6.312
Authors: Rodrigo B Mansur; Francheska Delgado-Peraza; Mehala Subramaniapillai; Yena Lee; Michelle Iacobucci; Flora Nasri; Nelson Rodrigues; Joshua D Rosenblat; Elisa Brietzke; Victoria E Cosgrove; Nicole E Kramer; Trisha Suppes; Charles L Raison; Andrea Fagiolini; Natalie Rasgon; Sahil Chawla; Carlos Nogueras-Ortiz; Dimitrios Kapogiannis; Roger S McIntyre Journal: J Psychiatr Res Date: 2020-12-04 Impact factor: 4.791
Authors: Francheska Delgado-Peraza; Carlos J Nogueras-Ortiz; Olga Volpert; Dong Liu; Edward J Goetzl; Mark P Mattson; Nigel H Greig; Erez Eitan; Dimitrios Kapogiannis Journal: Cells Date: 2021-04-23 Impact factor: 6.600